Coeptis Therapeutics Holdings, Inc. (COEP)

COEP Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	0.08	0.03
Revenue Growth (YoY)	-	-	-	143.81%	27.68%
Cost of Revenue	-	-	-	-	0.96
Gross Profit	-	-	-	0.08	-0.93
Selling, General & Admin	5.62	13.35	34.18	14.12	5.78
Research & Development	2.33	6.67	0.02	-	0
Operating Expenses	10.05	21.49	34.2	14.12	5.78
Operating Income	-10.05	-21.49	-34.2	-14.05	-6.71
Interest Expense	-0.4	-0.11	-0.22	-0.19	-0.15
Other Non Operating Income (Expenses)	-0.19	0.33	0.01	0.79	-2.29
EBT Excluding Unusual Items	-10.64	-21.27	-34.41	-13.45	-9.16
Gain (Loss) on Sale of Assets	-	-	-	-0	-
Asset Writedown	-0.04	-	-	-	-
Other Unusual Items	-0.2	-	-3.17	-	-
Pretax Income	-10.88	-21.27	-37.57	-13.45	-9.16
Earnings From Continuing Operations	-10.88	-21.27	-37.57	-13.45	-9.16
Minority Interest in Earnings	1.06	-	-	-	-
Net Income	-9.81	-21.27	-37.57	-13.45	-9.16
Net Income to Common	-9.81	-21.27	-37.57	-13.45	-9.16
Shares Outstanding (Basic)	2	1	1	1	0
Shares Outstanding (Diluted)	2	1	1	1	0
Shares Change (YoY)	49.84%	79.70%	30.98%	79.11%	18.53%
EPS (Basic)	-5.10	-16.56	-52.57	-24.64	-30.05
EPS (Diluted)	-5.10	-16.56	-52.57	-24.64	-30.05
Free Cash Flow	-6.65	-7.24	-3.88	-4.49	-3.14
Free Cash Flow Per Share	-3.46	-5.64	-5.42	-8.23	-10.29
Gross Margin	-	-	-	100.00%	-
Operating Margin	-	-	-	-18727.91%	-21823.77%
Profit Margin	-	-	-	-17932.37%	-29765.89%
Free Cash Flow Margin	-	-	-	-5985.92%	-10195.12%
EBITDA	-9.05	-20.49	-33.19	-13.6	-6.39
D&A For EBITDA	1	1	1	0.45	0.32
EBIT	-10.05	-21.49	-34.2	-14.05	-6.71
Revenue as Reported	-	-	-	0.08	0.03

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q